Pure Global
NCT06108726

A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer

A Single-arm, Exploratory Clinical Trial Investigating the Efficacy of Local Envafolimab Injection Under Fiberoptic Bronchoscopy Combined With Chemotherapy in Non-small Cell Lung Cancer
Northern Jiangsu Province People's Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
Envafolimab Injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Northern Jiangsu Province People's Hospital
Location
Suzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Oct 18, 2023
End date
Oct 18, 2025
Enrollment
16 participants
Primary outcome

Overall Survival(OS),Objective Response Rate(ORR),Progression free survival(PFS)

Summary

The aim of this single-arm, exploratory clinical study is to evaluate the safety and efficacy
 of local injection of envafolimab combined with chemotherapy in the first-line treatment of
 non-small cell lung cancer (NSCLC) patients, and to observe the changes of immune cells in
 the local immune microenvironment before and after immunotherapy, in order to find new
 indicators for immunotherapy evaluation.

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06108726
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06108726 through Pure Global AI's free database. This Phase 2 trial is sponsored by Northern Jiangsu Province People's Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 16 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.